Panelists discuss Melinda's treatment journey for advanced EGFR-mutant NSCLC, including the specific treatments she received and her responses, while Dr. Spira provides a high-level overview of systemic therapies for the condition, highlighting the role of amivantamab and how management strategies are tailored based on patient and disease characteristics, with treatment decisions guided by available data.
Video content above is prompted by the following:
Stay up to date on recent advances in the multidisciplinary approach to cancer.
2 Commerce Drive
Cranbury, NJ 08512